Identification of serum biomarkers for evaluating seizure outcome after resective epilepsy surgery

doi:10.5246/jcps.2020.08.050

Abstract

Abstract:

Although patients with drug-resistant temporal lobe epilepsy (TLE) achieve good seizure control with resective surgery combined with anti-epileptic drugs (AEDs) treatment, it is still not clear when to withdraw AEDs after the surgery due to a lack of objective strategy for assessing the surgery outcome. Our aim is to identify objective and efficient biomarkers for assessment of surgery outcome to guide postoperative pharmacotherapy. Here, we detected 469 proteins differentially expressed between pre- and post-operative sera of TLE patients with postoperative seizure freedom, and identified six candidate proteins (HBA1, HBB, PRDX2, CA1, CAT and BLVRB) for validation. These six proteins were significantly reduced within three months after surgery, indicating these proteins may be potential biomarkers to assess the surgery outcome for TLE patients in the early stage. Interestingly,we found HBA1 to HBB ratio was superior to individual proteins to evaluate the postoperative surgery outcome with 90.0% sensitivity, 90% specificity and area under the curve of 0.960. We also suppose these proteins were derived from epilepsy foci due to the rat experiment results that HBA1, HBB, PRDX2, CA1 and CAT were highly expressed in cerebrospinal fluid of epilepsy rat models. Additionally, HBA1, HBB, PRDX2, CA1 and BLVRB proteins were highly expressed in the sera of TLE patients with postoperative seizure freedom when compared to TLE patients with postoperative seizure and patients with other types of epilepsy, suggesting surgery outcome or the original sites of seizure might be assessed before the operation through monitoring these protein levels in the sera. Our study provides experimental data for establishing objective indicators for assessing seizure freedom after resective surgery and also proposed potential markers for specific diagnoses of TLE and prediction of TLE surgery outcome.

Key words: Temporal lobe epilepsy, Surgery outcome, Biomarker, Serum

CLC Number:

R969

Supporting:

Qian Chen, Xuyang Zhao, Yujing Song, Shaoyi Li, Wanyu Lei, Weining Ma, Zhuo Huang. Identification of serum biomarkers for evaluating seizure outcome after resective epilepsy surgery[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 528-541.

References

[1] Wiebe, S.; Blume, W.T.; Girvin, J.P.; Eliasziw, M.; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 2001, 345, 311-318.

[2] Engel, J. Jr, McDermott, M.P.; Wiebe, S.; Langfitt, J.T.; Stern, J.M.; Dewar, S.; Sperling, M.R.; Gardiner, I.; Erba, G.; Fried, I.; Jacobs, M.; Vinters, H.V.; Mintzer, S.; Kieburtz, K.; Early Randomized Surgical Epilepsy Trial (ERSET) Study Group. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012, 307, 922-930.

[3] Helmstaedter, C.; Elger, C.E.; Witt, J.A. The effect of quantitative and qualitative antiepileptic drug changes on cognitive recovery after epilepsy surgery. Seizure. 2016, 36, 63-69.

[4] Rathore, C.; Jeyaraj, M.K.; Dash, G.K.; Wattamwar, P.; Baheti, N.; Sarma, S.P.; Radhakrishnan, K. Outcome after seizure recurrence on antiepileptic drug withdrawal following temporal lobectomy. Neurology. 2018, 91, e208-e216.

[5] Schmidt, D.; Bertram, E.; Ryvlin, P.; Lüders, H.O. The impact of temporal lobe surgery on cure and mortality of drug-resistant epilepsy: summary of a workshop. Epilepsy Res. 2003, 56, 83-84.

[6] Schmidt, D.; Baumgartner, C.; Löscher, W. The chance of cure following surgery for drug-resistant temporal lobe epilepsy. What do we know and do we need to revise our expectations? Epilepsy Res. 2004, 60, 187-201.

[7] Zhang, L.; Jiang, X.Y.; Zhou, D.; Zhang, H.; Bao, S.M.; Li, J.M. Postoperative seizure outcome and timing interval to start antiepileptic drug withdrawal: a retrospective observational study of non-neoplastic drug resistant epilepsy. Sci. Rep. 2018, 8, 13782.

[8] Cramer, J.A.; Mintzer, S.; Wheless, J.; Mattson, R.H. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert. Rev. Neurother. 2010, 10, 885-891.

[9] Radhakrishnan, K. Challenges in the management of epilepsy in resource-poor countries. Nat. Rev. Neurol. 2009, 5, 323-330.

[10] Wieser, H.G.; Blume, W.T.; Fish, D.; Goldensohn, E.; Hufnagel, A.; King, D.; Sperling, M.R.; Lüders, H.; Pedley, T.A.; Commission on Neurosurgery of the International League Against Epilepsy (ILAE). ILAE Commission Report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia. 2001, 42, 282-286.

[11] Engel, J. Jr, Wiebe, S.; French, J.; Sperling, M.; Williamson, P.; Spencer, D.; Gumnit, R.; Zahn, C.; Westbrook, E.; Enos, B. Quality Standards Subcommittee of the American Academy of Neurology, American Epilepsy Society, American Association of Neurological Surgeons. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the quality standards subcommittee of the American academy of neurology, in association with the American epilepsy society and the American association of neurological surgeons. Neurology. 2003, 60, 538-547.

[12] Durnford, A.J.; Rodgers, W.; Kirkham, F.J.; Mullee, M.A.; Whitney, A.; Prevett, M.; Kinton, L.; Harris, M.; Gray, W.P. Very good inter-rater reliability of Engel and ILAE epilepsy surgery outcome classifications in a series of 76 patients. Seizure. 2011, 20, 809-812.

[13] van Dijkman, S.C.; Voskuyl, R.A.; de Lange, E.C. Biomarkers in epilepsy-A modelling perspective. Eur. J. Pharm. Sci. 2017, 109S, S47-S52.

[14] He, X.S.; Doucet, G.E.; Pustina, D.; Sperling, M.R.; Sharan, A.D.; Tracy, J.I. Presurgical thalamic ―hubness‖ predicts surgical outcome in temporal lobe epilepsy. Neurology. 2017, 88, 2285-2293.

[15] Morgan, V.L.; Englot, D.J.; Rogers, B.P.; Landman, B.A.; Cakir, A.; Abou-Khalil, B.W.; Anderson, A.W. Magnetic resonance imaging connectivity for the prediction of seizure outcome in temporal lobe epilepsy. Epilepsia. 2017, 58, 1251-1260.

[16] Bonilha, L.; Jensen, J.H.; Baker, N.; Breedlove, J.; Nesland, T.; Lin, J.J.; Drane, D.L.; Saindane, A.M.; Binder, J.R.; Kuzniecky, R.I. The brain connectome as a personalized biomarker of seizure outcomes after temporal lobectomy. Neurology. 2015, 84, 1846-1853.

[17] Suhy, J.; Laxer, K.D.; Capizzano, A.A.; Vermathen, P.; Matson, G.B.; Barbaro, N.M.; Weiner, M.W. 1H MRSI predicts surgical outcome in MRI-negative temporal lobe epilepsy. Neurology. 2002, 58, 821-823.

[18] Boersema, P.J.; Raijmakers, R.; Lemeer, S.; Mohammed, S.; Heck, A.J. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat. Protoc. 2009, 4, 484-494.

[19] Liu, Y.Q.; Lai, S.R.; Ma, W.N.; Ke, W.; Zhang, C.; Liu, S.M.; Zhang, Y.; Pei, F.; Li, S.Y.; Yi, M.; Shu, Y.S.; Shang, Y.F.; Liang, J.; Huang, Z. CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression. Nat. Commun. 2017, 8, 355.

[20] Pegg, C.C.; He, C.Y.; Stroink, A.R.; Kattner, K.A.; Wang, C.X. Technique for collection of cerebrospinal fluid from the cisterna Magna in rat. J. Neurosci. Methods. 2010, 187, 8-12.

[21] de Araújo, J.T.; Ribeiro, V.S.; de Araújo, R.A. Hemoglo-binopathies: molecular, genetic and clinical aspects. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 1987, 42, 260-266.

[22] Mills, F.C.; Ackers, G.K. Quaternary enhancement in binding of oxygen by human hemoglobin. Proc. Natl. Acad. Sci. USA. 1979, 76, 273-277.

[23] Ascenzi, P.; Gustincich, S.; Marino, M. Mammalian nerve globins in search of functions. IUBMB Life. 2014, 66, 268-276.

[24] Richter, F.; Meurers, B.H.; Zhu, C.N.; Medvedeva, V.P.; Chesselet, M.F. Neurons express hemoglobin alpha- and beta-chains in rat and human brains. J. Comp. Neurol. 2009, 515, 538-547.

[25] Schelshorn, D.W.; Schneider, A.; Kuschinsky, W.; Weber, D.; Krüger, C.; Dittgen, T.; Bürgers, H.F.; Sabouri, F.; Gassler, N.; Bach, A.; Maurer, M.H. Expression of hemoglobin in rodent neurons. J. Cereb. Blood Flow Metab. 2009, 29, 585-595.

[26] Codrich, M.; Bertuzzi, M.; Russo, R.; Francescatto, M.; Espinoza, S.; Zentilin, L.; Giacca, M.; Cesselli, D.; Beltrami, A.P.; Ascenzi, P.; Zucchelli, S.; Persichetti, F.; Leanza, G.; Gustincich, S. Neuronal hemoglobin affects dopaminergic cells‘ response to stress. Cell Death Dis. 2017, 8, e2538.

[27] Brown, N.; Alkhayer, K.; Clements, R.; Singhal, N.; Gregory, R.; Azzam, S.; Li, S.; Freeman, E.; McDonough, J. Neuronal hemoglobin expression and its relevance to multiple sclerosis neuropathology. J. Mol. Neurosci. 2016, 59, 1-17.

[28] Biagioli, M.; Pinto, M.; Cesselli, D.; Zaninello, M.; Lazarevic, D.; Roncaglia, P.; Simone, R.; Vlachouli, C.; Plessy, C.; Bertin, N.; Beltrami, A.; Kobayashi, K.; Gallo, V.; Santoro, C.; Ferrer, I.; Rivella, S.; Beltrami, C.A.; Carninci, P.; Raviola, E.; Gustincich, S. Unexpected expression of α- and β-globin in mesencephalic dopaminergic neurons and glial cells. Proc. Natl. Acad. Sci. USA. 2009, 106, 15454-15459.

[29] Pugliese, P.T. The skin‘s antioxidant systems. Dermatol. Nurs. 1998, 10, 401-416; quiz 417-418.

[30] Barros, D.O.; Xavier, S.M.; Barbosa, C.O.; Silva, R.F.; Freitas, R.L.; Maia, F.D.; Oliveira, A.A.; Freitas, R.M.; Takahashi, R.N. Effects of the vitamin E in catalase activities in Hippocampus after status epilepticus induced by pilocarpine in Wistar rats. Neurosci. Lett. 2007, 416, 227-230.

[31] Rumià, J.; Marmol, F.; Sanchez, J.; Giménez-Crouseilles, J.; Carreño, M.; Bargalló, N.; Boget, T.; Pintor, L.; Setoain, X.; Donaire, A.; Saez, G.T.; Ribalta, T.; Ferrer, E.; Puig-Parellada, P. Oxidative stress markers in the neocortex of drug-resistant epilepsy patients submitted to epilepsy surgery. Epilepsy Res. 2013, 107, 75-81.

[32] Devi, P.U.; Manocha, A.; Vohora, D. Seizures, antiepileptics, antioxidants and oxidative stress: an insight for researchers. Expert. Opin. Pharmacother. 2008, 9, 3169-3177.

[33] De Haes, W.; Frooninckx, L.; van Assche, R.; Smolders, A.; Depuydt, G.; Billen, J.; Braeckman, B.P.; Schoofs, L.; Temmerman, L. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc. Natl. Acad. Sci. USA. 2014, 111, E2501-E2509.

[34] Lee, S.H.; Choi, B.Y.; Kho, A.R.; Jeong, J.H.; Hong, D.K.; Kang, D.H.; Kang, B.S.; Song, H.K.; Choi, H.C.; Suh, S.W. Inhibition of NADPH oxidase activation by apocynin rescues seizure-induced reduction of adult hippocampal neurogenesis. Int. J. Mol. Sci. 2018, 19, E3087.

[35] Domsic, J.F.; Avvaru, B.S.; Kim, C.U.; Gruner, S.M.; Agbandje-McKenna, M.; Silverman, D.N.; McKenna, R. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J. Biol. Chem. 2008, 283, 30766-30771.

[36] Aggarwal, M.; Kondeti, B.; McKenna, R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert. Opin. Ther. Pat. 2013, 23, 717-724.

[37] Ruusuvuori, E.L.; Huttu, K.; Palva, J.M.; Smirnov, S.; Rivera, C.K.L.; Voipio, J. Carbonic anhydrase isoform VII Acts as a molecular switch in the development of synchronous Gamma-frequency firing of hippocampal CA1 pyramidal cells. J. Neurosci. 2004, 24, 2699-2707.

[38] Shih, Y.H.; Yen, A.M.; Yen, D.J.; Hung, L.P.; Chen, H.H.; Liou, H.H. A novel postoperative seizure classification for long-term mortality of patients with intractable epilepsy: comparison with the Engel system. Neurosurgery. 2011, 69, 64-70; discussion 70-71.

[39] Harden, C.L.; Pennell, P.B.; French, J.A.; Davis, A.; Lau, C.; Llewellyn, N.; Kaufman, B.; Bagiella, E.; Kirshenbaum, A. Anti-Mullerian hormone is higher in seizure-free women with epilepsy compared to those with ongoing seizures. Epilepsy Res. 2016, 127, 66-71.

[40] Kwan, P.; Li, H.M.; Al-Jufairi, E.; Abdulla, R.; Gonzales, M.; Kaye, A.H.; Szoeke, C.; Ng, H.K.; Wong, K.S.; O‘Brien, T.J. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol. Dis. 2010, 39, 192-197.

[41] Wu, Y.; Liu, D.; Song, Z. Neuronal networks and energy bursts in epilepsy. Neuroscience. 2015, 287, 175-186.

[42] Berger, R.P.; Pak, B.J.; Kolesnikova, M.D.; Fromkin, J.; Saladino, R.; Herman, B.E.; Pierce, M.C.; Englert, D.; Smith, P.T.; Kochanek, P.M. Derivation and validation of a serum biomarker panel to identify infants with acute intracranial hemorrhage. JAMA Pediatr. 2017, 171, e170429.

[43] Galovic, M.; Döhler, N.; Erdélyi-Canavese, B.; Felbecker, A.; Siebel, P.; Conrad, J.; Evers, S.; Winklehner, M.; von Oertzen, T.J.; Haring, H.P.; Serafini, A.; Gregoraci, G.; Valente, M.; Janes, F.; Gigli, G.L.; Keezer, M.R.; Duncan, J.S.; Sander, J.W.; Koepp, M.J.; Tettenborn, B. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurol. 2018, 17, 143-152.

[44] Rubenstein, R.; Chang, B.G.; Yue, J.K.; Chiu, A.; Winkler, E.A.; Puccio, A.M.; Diaz-Arrastia, R.; Yuh, E.L.; Mukherjee, P.; Valadka, A.B.; Gordon, W.A.; Okonkwo, D.O.; Davies, P.; Agarwal, S.; Lin, F.; Sarkis, G.; Yadikar, H.; Yang, Z.H.; Manley, G.T.; Wang, K.K.W.; Cooper, S.R.; Dams-O‘connor, K.; Borrasso, A.J.; Inoue, T.; Maas, A.I.R.; Menon, D.K.; Schnyer, D.M.; Vassar, M.J.; the TRACK-TBI Investigators, A. Comparing plasma phospho tau, total tau, and phospho tau-total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol. 2017, 74, 1063.